데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
123663-49-0CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1ANMATWQYLIFGOK-UHFFFAOYSA-N123663-49-0DTXSID0048971CHEMBL2107455CHEBI:31689안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.
용도Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.
불러오는 중…